HLB Group announced on April 1 that Chairman Jin Yang-gon purchased 59,619 shares of HLB Genex through on-market transactions.


Chairman Jin Yang-gon Purchases HLB Genex Shares: "Transitioning to a Bio-Healthcare Materials Company" View original image

This move reaffirms his confidence in the future value of HLB Genex, which earlier this year declared its transition into a "bio-healthcare materials solutions company." HLB Genex stated that Chairman Jin acquired 59,619 shares of the company over a five-day period starting from March 24. As a result, Jin's total holdings in HLB Genex have increased to 533,294 shares.


This share purchase is an extension of the ongoing trend of increasing stakes in key listed affiliates within the group. Chairman Jin has expanded his equity primarily in affiliates that are about to achieve major milestones or are pursuing next-generation businesses. Earlier this year, Jin acquired 207,000 shares of HLB Innovation, 390,811 shares of HLB Panagene, and 52,531 shares of HLB Therapeutics.


HLB Genex, after being integrated into the HLB Group for just one year, succeeded in turning a profit and simultaneously improved its performance and fundamentals. In addition to the stable growth of its flagship enzyme products, Catalase and Lactase, the company expanded its portfolio of high-value-added products with the launch of the new enzyme product UDCAse, recording sales of 43.4 billion won and an operating profit of 1.2 billion won last year.


The company is striving to become a bio-healthcare materials solutions provider. It is building a business structure that encompasses the entire spectrum of bio-healthcare materials beyond enzymes, and is launching a customized bio-materials business based on its one-stop solution capabilities, which cover everything from R&D and strain development/improvement to process development and production for target substances of external clients. In parallel, the company is pursuing the development of treatments for brain diseases such as Parkinson's disease through its subsidiary HLB Neurotov, thereby securing future growth engines to further enhance corporate value.



An HLB Genex representative stated, "This share acquisition reflects our confidence in the company's growth strategy and future value transformation," adding, "We will elevate our corporate value by advancing beyond an enzyme specialist to become a bio-healthcare materials solutions company."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing